PTACH - Moligand™, 10 mM in DMSO , CAS No.848354-66-5

CAS: 848354-66-5 Cat. No.: P1495987 Formule: C20H26N2O2S2 Poids moléculaire: 390.57 Numéro CE: 635-730-4
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10 mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Taille
Allemagne (EU)
USA*
Prix
Qté
1ml
P1495987-1ml
Sur commande · 8–12 semaines
121,40€
Enter a quantity for the sizes you want to add.

Vue d’ensemble

PTACH (NCH-51) is a potent HDAC inhibitor with IC 50 s of 48 nM, 32 nM, and 41 nM for HDAC1 , HDAC4 , and HDAC6 , respectively. PTACH exerts potent growth inhibition against various cancer cells (EC 50 s of 1.1-9.1 μM) .

Spécifications

Spécifications et pureté
Moligand™, 10 mM in DMSO
Conditions de stockage de stockage
Store at -80°C
Expédié en
Dry ice packs + Cold packs
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Grade
Moligand™
Type d'action
ACTIVATOR
Noms et identifiants
Isomères SMILES
CC(C)C(=O)SCCCCCCC(=O)NC1=NC(=CS1)C2=CC=CC=C2
Poids moléculaire
390.57
Reaxys
9943595
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9943595&ln=

Données avancées

Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Sécurité et dangers (GHS)
Signal
Danger
Mentions de danger

H318:Causes serious eye damage

H413:May cause long lasting harmful effects to aquatic life

Reaxys
9943595
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9943595&ln=
Calculateurs de solution
Avis

Avis des clients

Application Protocols
  • Item-specific validated applications and conditions: Not specified for this item.

  • General protocols for small-molecule screening (not item-specific)

    • Biochemical enzyme assay: Prepare 10 mM DMSO stock; dose to final 0.5% DMSO, incubate with enzyme and substrate under optimized conditions; include vehicle and positive controls.
    • Thermal shift (DSF): Mix protein with dye and serial dilutions of compound in low-salt buffer with 1–2% DMSO; record Tm shifts and assess aggregation controls.
    • SPR binding: Prepare matched-buffer DMSO stocks; perform solvent correction; screen at multi-concentration series with reference subtraction.
    • Note: Tailor concentrations and conditions to your specific targets; validate solubility and stability prior to runs.
Biological Roles
  • Item-specific biological role: Not specified for this item; refer to CoA/Spec Sheet and literature for CAS 848354-66-5.

  • General context for small-molecule ligands (not item-specific)

    • Small molecules may act as binders, inhibitors, activators, or chemical probes in cellular or biochemical pathways. The precise role depends on structure and target engagement, which are not provided here.
    • Prior to biological testing, determine or request the complete structure and any known bioactivity annotations to ensure appropriate hazard assessments and assay design.
  • Research use limitation

    • For research use only. Not for human or veterinary applications, clinical diagnostics, or household use.
Buffer Applications
  • Applicability

    • PTACH is a small-molecule library member rather than a buffering agent. It is not typically used to prepare or control buffer pH.
  • Practical note

    • If assayed in aqueous buffers, ensure compatibility of the compound with the buffer components (salts, detergents, reducing agents). Optimize co-solvent content (commonly 0.1–1% DMSO) to maintain solubility during dilutions.
Green Alternatives
  • Applicability

    • Without structural and solvent-use context, green alternatives can only be discussed at the level of handling and formulation practices rather than replacement reagents.
  • Greener handling practices for small-molecule libraries (general)

    • Use minimal DMSO volumes consistent with assay needs; consider aqueous-first dilutions where feasible.
    • Replace chlorinated solvents during cleanup/workup with ethyl acetate or 2-MeTHF when compatible (general suggestion; verify compound stability).
    • Where heating is needed for dissolution, prefer closed-vial block heaters to reduce emissions; avoid open hotplates.
  • Solvent comparison (general guidance; not item-specific)

    • DMSO vs DMF: DMSO favored for biocompatibility and lower volatility; DMF has higher toxicity concerns.
    • ACN vs MeOH/EtOH: ACN is MS-friendly but has higher environmental burden; MeOH/EtOH are greener but may affect assay readouts.
  • Waste minimization

    • Plate at high concentration stocks to reduce shipping/handling volume. Consolidate mother plates and use acoustic dispensing to cut solvent waste.
Pharmaceutical Uses
  • Item-specific pharmacopeial/excipient status: Not specified for this item; no pharmacopeial monograph indicated.

  • Context

    • As a Moligand™ small-molecule library compound, PTACH is intended for research screening and discovery workflows. It is not supplied for drug product manufacturing or as a GMP excipient.
  • Formulation notes for research only (not for human use)

    • Prepare DMSO stock solutions under low-moisture conditions. If evaluating in preclinical research assays, document vehicle composition, dose solution stability, and any observed precipitation or adsorption to plastics.
Physical Properties
  • Item-specific properties (from Product Data)

    • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Literature/computed values

    • Boiling point, melting point, density, refractive index, logP, pKa, UV cutoffs: Not available for this item; consult the CoA/SDS or primary literature for CAS 848354-66-5 if needed.
  • Solubility guidance (general best practices for screening compounds; not item-specific)

    • Initial solvent: Anhydrous DMSO is typically used for small-molecule libraries at 10–50 mM stock; confirm compatibility once structure/functional groups are known.
    • Alternative solvents: DMF, ethanol, methanol, acetonitrile, or aqueous buffers with co-solvent can be explored by small-scale solubility tests (serial dilution, visual inspection, nephelometry).
  • Notes on hygroscopicity and stability

    • Without specific data, assume potential sensitivity to moisture, oxygen, and light. Work quickly at ambient temperature and return to −80°C storage to minimize degradation.
Quality and Grades
  • Item-specific grade (from Product Data)

    • Grade/Purity: Moligand™.
  • What Moligand™ typically implies (general explanation; not a specification)

    • Intended for research screening of molecular interactions (e.g., binding, SAR exploration, chemical biology). Such collections generally emphasize confirmed identity and consistent lot-to-lot performance for library use.
    • Typical QC elements for library compounds may include structure confirmation (e.g., NMR/HRMS), purity checks (e.g., HPLC/UPLC), and documentation via CoA. Specific acceptance criteria are not provided here.
  • Explicit non-provided specifications (do not infer)

    • Water content, residual solvents, metal content, stabilizers, counter-ions/salt form, and UV absorbance characteristics: Not specified for this item; refer to CoA/Spec Sheet.
  • Practical guidance

    • For plate-based screening, pre-test solubility and stability in the chosen assay buffer and DMSO concentration. Record lot and plate maps. If using for biophysical assays (SPR/ITC/DSF), filter stocks (0.2 μm PTFE) when compatible, and quantify concentration by weight and, if possible, by UV/LC.
Reaction and Applications
  • Item-specific reaction behavior: Not specified for this item; structural details are required to discuss reactivity.

  • Research applications (general to Moligand™ small molecules; not item-specific)

    • Ligand discovery and screening: Use in biochemical or biophysical assays (e.g., enzyme inhibition, binding displacement, thermal shift) to identify hits.
    • Cellular probe evaluation: Preliminary assessment of permeability, cytotoxicity windows, and target engagement using non-clinical research assays.
    • Analytical reference: Use as an internal or external standard if structurally suitable and characterized in-house.
  • Practical tips

    • Prepare replicate stocks and include vehicle controls. Track freeze–thaw cycles to reduce variability.
    • Assess compound aggregation (detergent controls, DLS) and redox activity (PAINS assays) when screening to reduce false positives.
    • If proceeding to chemistry optimization, request or determine full structural data to enable SAR and derivatization strategies.
Reaction Conditions
  • Item-specific reaction conditions and yields: Not specified for this item; refer to primary literature for CAS 848354-66-5 if applicable.

  • General guidance for handling in assay preparation (not synthetic chemistry)

    • Stock preparation: 10–50 mM in dry DMSO; vortex and, if necessary, sonicate briefly. Filter through 0.2 μm PTFE if compatible.
    • Dilution: Add DMSO stock to buffer as the final step while vortexing to avoid local supersaturation; typical final DMSO 0.1–1%.
    • Stability checks: Reassess after 24–72 h at assay temperature for precipitation, discoloration, or chromatographic degradation.
Safety and Handling
  • GHS information (from Product Data)

    • Signal word: Not specified for this item; refer to SDS.
    • H-statements: Not specified for this item; refer to SDS.
    • GHS classification: Not specified for this item; refer to SDS.
    • Pictograms: Not specified for this item; refer to SDS.
  • General laboratory precautions (not item-specific; follow institutional EHS requirements)

    • PPE: Lab coat, nitrile gloves, safety glasses. Use a certified chemical fume hood to avoid inhalation exposure during weighing or preparation.
    • Avoid contact with skin, eyes, and clothing; prevent ingestion and inhalation. Wash hands thoroughly after handling.
    • Storage incompatibilities: Until structural class is verified, segregate from strong oxidizers, strong acids/bases, and reducing agents. Keep container tightly closed under dry, inert conditions at −80°C as specified.
  • First-aid overview (consult SDS for definitive instructions)

    • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
    • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; obtain medical advice.
    • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
  • Special risks

    • Unknown sensitization or toxicity profile. Minimize aerosol generation, avoid open handling, and label all intermediate vials/plates used in screening.
Solvent Selection
  • Item-specific solubility: Not specified for this item; refer to CoA/Spec Sheet.

  • General strategy for small-molecule library members (not item-specific)

    • Primary solvent: Anhydrous DMSO (≥99.9%) for 10–50 mM stocks; store at −20 to −80°C in tightly sealed, low-bind vials.
    • Screening dilutions: Into assay buffer with final DMSO 0.1–1% v/v; confirm assay tolerance to DMSO.
    • Alternative organic solvents: DMF, acetonitrile, methanol, ethanol can be used for intermediate dilutions; evaluate stability and potential assay interference (e.g., ACN in MS workflows; MeOH/EtOH for biochemical assays).
    • Aqueous compatibility: If ionizable functionalities are known (not provided here), adjust pH to enhance solubility; consider co-solvent systems or cyclodextrin inclusion where appropriate.
  • Selection tips

    • If the compound is hydrophobic (visual cues: rapid precipitation upon aqueous dilution), increase DMSO carryover or use gentle heating/sonication.
    • For sensitive assays (fluorescence), use high-purity, low-fluorescence solvents and verify compound autofluorescence independently.
Storage and Reconstitution
  • Item-specific storage and shipping (from Product Data)

    • Storage conditions: Store at −80°C.
    • Shipped in: Dry ice packs + Cold packs.
  • Reconstitution guidance (general; not item-specific)

    • Allow vials to equilibrate to room temperature in a desiccator before opening to prevent moisture condensation.
    • Prepare concentrated stocks in anhydrous DMSO. Record concentration, solvent, date, and number of freeze–thaw cycles.
    • Aliquot into inert, low-bind vials or plates to minimize freeze–thaw. Backfill headspace with dry nitrogen or argon where possible.
    • For aqueous working solutions, dilute immediately before use; avoid long-term storage in water-containing media unless stability is verified.
  • Stability notes

    • Protect from light if chromophores are suspected; use amber vials as a precaution.
    • If precipitation occurs after thawing, gently warm (≤40°C) and vortex/sonicate briefly; do not overheat. Discard if persistent insolubility or discoloration is observed.
  • Documentation

    • Retain CoA/Spec Sheet and SDS with the stored material. Track lot numbers in all experiments. For research use only.
Structure and Identity
  • Item-specific identifiers (from Product Data)

    • CAS: 848354-66-5
    • Product name: PTACH (Moligand™)
    • SKU: P1495987
    • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
    • PubChem CID: 11395181 (identifier only; consult literature/SDS for structure details).
  • Structural features

    • 2D/3D structure description: Not specified for this item; refer to CoA/Spec Sheet.
    • Functional groups, ring systems, stereochemistry: Not specified for this item; refer to CoA/Spec Sheet.
  • Notes

    • PTACH is listed within a small-molecule/compound library (Moligand™). Without a disclosed structure, treat as an unknown small molecule for handling and solution preparation. Always verify identity via the supplied CoA/SDS prior to experimental use.
Synthetic Utility
  • Applicability

    • Synthetic transformations and functional-group reactivity cannot be discussed without the disclosed structure. No claims are made regarding building-block utility for PTACH.
  • General note

    • If structural information is obtained, assess handles for diversification (e.g., halides for cross-coupling, amines/acids for amide formation). Consider late-stage functionalization strategies only after confirming stability and purity.
Target Specificity
  • Item-specific target(s), epitope(s), or binding profile: Not specified for this item; refer to CoA/Spec Sheet and literature for any known bioactivity associated with CAS 848354-66-5.

  • Guidance

    • For screening use, include orthogonal assays to confirm any apparent activity and to exclude assay interference or colloidal aggregation.

Besoin d'aide pour choisir la qualité ?

Notre guide de sélection des qualités couvre la pureté, le statut du stabilisant et l'adéquation à l'application pour toutes les variantes de notre catalogue.

Voir le guide des qualités Moligand™ →

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.